Machine signal
Active cluster sell — 3 distinct insiders, $32.1M, window ends Oct 1, 2026.
Figures computed from official regulatory filings — .
Analysttarget 228.89 USD (+52%) · consensus 4.78/5 · 9 buy · 0 hold · 0 sell
Ownershipinsiders 43.65% · institutions 24.27% · short 5.0% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BELITE BIO, INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
175 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Scholl Hendrik Peter | Sell | $8.3K | SEC |
| Scholl Hendrik Peter | Sell | $2.4K | SEC |
| Scholl Hendrik Peter | Sell | $4K | SEC |
| Scholl Hendrik Peter | Sell | $340 | SEC |
| Scholl Hendrik Peter | Sell | $13.1K | SEC |
| Scholl Hendrik Peter | Sell | $32.7K | SEC |
| Scholl Hendrik Peter | Sell | $2K | SEC |
| Scholl Hendrik Peter | Sell | $19.9K | SEC |
| Chuang Hao-Yuan | Sell | $365K | SEC |
| Lin Yu-Hsin | Sell | $1.2M | Unusual size | SEC |
| Lin Yu-Hsin | Sell | $114.2K | SEC |
| Lin Yu-Hsin | Sell | $1.2M | Unusual size | SEC |
| Chuang Hao-Yuan | Sell | $1.2M | Unusual size | SEC |
| Lin Yu-Hsin | Sell | $534.8K | SEC |
| Chuang Hao-Yuan | Sell | $805.9K | SEC |
| Chuang Hao-Yuan | Sell | $294.2K | SEC |
| Lin Yu-Hsin | Sell | $1.6M | Unusual size | SEC |
| Lin Yu-Hsin | Sell | $573.3K | SEC |
| Lin Yu-Hsin | Sell | $1.7M | Unusual size | SEC |
| Lin Yu-Hsin | Sell | $908.2K | Unusual size | SEC |
| Chuang Hao-Yuan | Sell | $1.2M | Unusual size | SEC |
| Chuang Hao-Yuan | Sell | $362.1K | SEC |
| Lin Yu-Hsin | Sell | $1.5M | Unusual size | SEC |
| Chuang Hao-Yuan | Sell | $358.3K | SEC |
| Chuang Hao-Yuan | Sell | $729.9K | Unusual size | SEC |